Co-targeting CDK4/6 and AKT with endocrine therapy prevents progression in CDK4/6 inhibitor and endocrine therapy-resistant breast cancer

CDK4/6 inhibitors (CDK4/6i) combined with endocrine therapy have shown impressive efficacy in estrogen receptor-positive advanced breast cancer. However, most patients will eventually experience disease progression on this combination, underscoring the need for effective subsequent treatments or bet...

Descripción completa

Detalles Bibliográficos
Autores principales: Alves, Carla L., Ehmsen, Sidse, Terp, Mikkel G., Portman, Neil, Tuttolomondo, Martina, Gammelgaard, Odd L., Hundebøl, Monique F., Kaminska, Kamila, Johansen, Lene E., Bak, Martin, Honeth, Gabriella, Bosch, Ana, Lim, Elgene, Ditzel, Henrik J.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Nature Publishing Group UK 2021
Materias:
Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8387387/
https://www.ncbi.nlm.nih.gov/pubmed/34433817
http://dx.doi.org/10.1038/s41467-021-25422-9

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8387387/
https://www.ncbi.nlm.nih.gov/pubmed/34433817
http://dx.doi.org/10.1038/s41467-021-25422-9

Ejemplares similares